Top 3 Trends in the Global Pelvic Organ Prolapse Market

Vaginal mesh for pelvic organ prolapse
Upsylon™ Y-Mesh and Colpassist™ Vaginal Positioning Device. Retrieved from: Boston Scientific

COVID-19 did its fair share of damage and the Global Pelvic Organ Prolapse Market was severely impacted by the pandemic. In most regions, there has been a delay in both invasive diagnosis and treatments. Due to the invasive nature of the pelvic organ prolapse repair procedure, it is likely that the vast majority of cases will be delayed for months. Conservative treatment options including pelvic floor muscle training, weight loss, pads and pessaries are recommended as patients will not be required to undergo surgery. Despite this, three key trends are at play working within this constantly evolving market, which are further discussed throughout the blog.


Pelvic organ prolapse (POP) afflicts up to 50% of women who have had children or have undergone menopause. The lifetime risk of requiring surgery for this condition is approximately 11%. However, there are a number of alternative treatments to POP that do not involve meshes. 

Often times, the first step to treatment is to get fitted for a pessary device to uphold the pelvic organs. Other non-surgical courses of action include kegel exercise or biofeedback therapy. If these approaches do not suffice, then POP may be better treated via a surgical technique. However, even in that case, meshes are not the optimal choice. Although not considered in the scope of this report, bladder/vaginal slings or the use of native tissue may actually be safer options.


Trend #1: Sacrocolpopexy Market Set to Experience a Slight Increase

The sacrocolpopexy market is set to experience a slight increase caused by consistent procedure numbers and the major shift away from transvaginal mesh. Procedure numbers will remain stable simply because a high number of patients suffer from pelvic organ prolapse and there are few other surgical alternatives. While a native tissue repair can be performed in place of a mesh, the positive results are only temporary leading to a high rate of repeat procedures. Therefore, despite the controversy regarding mesh, it is still the recommended course of treatment.

Trend #2: Decline in ASPs

The ASP of these devices are expected to undergo a decline outside of COVID-19 related fluctuations as demand shifts from transvaginal mesh to sacrocolpopexy mesh, which has a lower average selling price. The market is set to decrease over the forecast period as the growth in unit sales for sacrocolpopexy meshes are offset by the significant decline in the transvaginal mesh market.

Trend #3: Transition to Trans-Abdominal Approach

Concerns over the transvaginal method of implanting organ prolapse mesh have driven physician usage of sacrocolpopexy mesh. The ban of all transvaginal meshes in the U.S. in 2019 is expected to significantly increase the share of sacrocolpopexy meshes within the pelvic organ prolapse repair device market elsewhere. This is also driven by a higher interest in minimally invasive as well as robotically assisted procedures, which can be done with sacrocolpopexy mesh.


Overall, the global pelvic organ prolapse market, covering 70 countries and 7 regions, experienced a substantial decrease in 2020, which encouraged an almost  43% decrease from the 2019 valuation. However, the market has started to increase moving into 2021 and is expected to reach just over $180 million by 2027. The value of the market increased in 2020, relative to 2019, due to demand from COVID-19 driven cases. Other factors such as demographic factors are expected to influence the market increase. For more information on procedures, unit sales, average selling prices, market drivers and limiters, competitive market share analysis, and more, follow the link below to receive a free research summary of the market. In addition, we offer our complete Global Gynecological Device Report Series which includes the pelvic organ prolapse segment.


FREE Sample Report


Leave a Reply